Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReMEDy1: DM199 in acute ischemic stroke
NCT03290560Phase 2Completed
- Sponsor
- DiaMedica Therapeutics
- Start
- Jan 2018
- Primary completion
- Jan 2020
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing DM199 with Placebo (2 arms). Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.3 at 90 Days. Started Jan 2018; status: completed.
02
Drugs
rinvecalinase alfa
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03290560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03290560.